多西他赛联合替吉奥治疗晚期胃印戒细胞癌26例临床观察

Clinical observation of docetaxel combined with S-1 in the treatment of 26 patients with advanced gastric signet ring cell cancer

目的:评价多西他赛联合替吉奥治疗晚期胃印戒细胞癌的疗效及毒副反应。方法:26例晚期胃印戒细胞癌患者接受多西他赛75mg/m2,静脉滴注,第1天;替吉奥80-120mg/m2,分两次口服,第1-14天,3周为一周期,4个周期后评价疗效及毒副反应,有效者改为替吉奥维持治疗至肿瘤进展或出现不可耐受的毒副反应。结果:可评价疗效26例,完全缓解(CR)0例,部分缓解(PR)11例,稳定(SD)11例,进展(PD)4例,总有效率(RR)11例(42.3%),中位肿瘤进展时间(mTTP)5.4个月,中位生存期(MST)9.2个月,主要不良反应为骨髓抑制、脱发。结论:多西他赛联合替吉奥治疗晚期胃印戒细胞癌具有较好的疗效,且不良反应可耐受。

Objective：To evaluate the efficacy and toxicities of docetaxel plus S-1 in the treatment of advanced gastric signet ring cell cancer.Methods： Total of 26 patients with advanced gastric signet ring cell cancer were treated with docetaxel 75mg/m2 on day 1 and S-1 80-120mg/m2（in two oral doses） for 14 days.The chemotherapy repeated every 3 weeks.Efficacy and toxicities were evaluated after 4 cycles of chemotherapy,patients who achieved remission were treated with S-1 until the disease progression or toxicity has become intolerable.Results： Of 26 patiens 0 case of complete response（CR） and 11 of partial response（PR）,11 of steadiness（SD） and 4 of progressive disease（PD）.Median time to progress（mTTP） was 5.4 months median survival time（MST） was 9.2 months.The main adverse reactions were myelosuppression,alopecia.Conclusion： The combination of docetaxel and S-1 is well tolerated and effecitive in the treatment of advanced gastric signet ring cell cancer.